摘要
勃起功能障碍(ED)是根治性前列腺切除术后主要的和最频繁的副作用。ED也是在患者进行前列腺根治性切除术后影响生活质量的主要影响因素。ED前列腺根除术后主要是因为病灶在其中可以发生由部分或全部切片的神经血管束损伤,通过拉伸(最常见的),或由神经纤维的热损伤,从而导致所谓的“神经失用症”。前列腺切除术后的阴茎复原(PR)术语已经被定义为任何具有使外科手术前的勃起功能复原目的干预,且包括磷酸二酯酶5抑制剂(PDE5i)分开或混合使用,海绵窦内的注射,真空勃起设备治疗,和尿道内药物的使用。海绵窦内药物,尿道内前列腺素以及真空治疗的应用有了一个关于术后阴茎复原的模糊不清的定义,且必须通过将来的研究来更好的调查。PDE5i作为PR的使用已经得到了实验研究数据的强烈支撑,但是大多数临床试验却显示了不同的结果。
关键词: 勃起功能障碍,阴茎勃起,前列腺切除术,阴茎功能,磷酸二酯酶型5抑制剂,前列腺癌,康复
Current Drug Targets
Title:Penile Rehabilitation After Radical Prostatectomy
Volume: 16 Issue: 5
Author(s): David Jacques Cohen and Sidney Glina
Affiliation:
关键词: 勃起功能障碍,阴茎勃起,前列腺切除术,阴茎功能,磷酸二酯酶型5抑制剂,前列腺癌,康复
摘要: Erectile dysfunction (ED) is the main and most frequent side effect after radical prostatectomy. Also, ED is the primary impact factor for quality of life after radical prostatectomy. ED post radical prostatectomy is mainly due to lesions in the neurovascular bundles which can occur by partial or total sectioning, by stretching (the most common), or by thermal lesion of the nervous fibers, leading to a condition called “neuropraxia”. The term penile rehabilitation (PR) after prostatectomy has been defined as any intervention with the intent of reestablishing preoperative erectile function and includes the isolated or combined use of phosphodiesterase 5 inhibitors (PDE5i), intracavernous injection, vacuum erectile device therapy, and use of intraurethral drugs. The use of intracavernous drugs, of intraurethral prostaglandin and the use of vacuum therapy have a poorly defined role regarding postoperative penile rehabilitation and must be better investigated through further studies. The use of PDE5i as PR is strongly supported by experimental research, but most clinical trials found controversial results.
Export Options
About this article
Cite this article as:
David Jacques Cohen and Sidney Glina , Penile Rehabilitation After Radical Prostatectomy, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450116666150202153832
DOI https://dx.doi.org/10.2174/1389450116666150202153832 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design The Role of Pemetrexed Combined with Gemcitabine for Non-Small-Cell Lung Cancer
Current Drug Targets Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Molecular Mechanism of Deguelin in Anti-tumor Effect
Current Pharmaceutical Analysis Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Exploration of the Potential Mechanisms of Compounds from <i>Rheum palmatum L.</i> against Chronic Obstructive Pulmonary Disease: A Network Pharmacology Study
Combinatorial Chemistry & High Throughput Screening Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Mitochondrial Superoxide Dismutase: A Promising Target for New Anticancer Therapies
Current Medicinal Chemistry Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Current Gene Therapy ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Current Pharmaceutical Design Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion
Current Molecular Medicine Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial
Reviews on Recent Clinical Trials Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
Current Pharmaceutical Design pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology